ArticleACS omega2026
The Synthesis and Anticancer Activity of the Trastuzumab-Doxorubicin Antibody-Drug Conjugate Using Strain-Promoted Alkyne-Azide Coupling.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) are target-specific drugs for the treatment of cancer. Fifteen antibody-drug conjugates have been approved so far for clinical use, while others remain in preclinical stages. We demonstrate here an example of the conjugation of a monoclonal antibody (trastuzumab) with a drug (doxorubicin) employing strain-promoted alkyne-azide coupling (SPAAC) reaction. This is an example of a "green" reaction because it is atom-efficient, and no side products are formed. The reaction is driven forward by release of strain in the triple bond of the seven-membered ring permitting regiospecific formation of triazole rings. Both trastuzumab and doxorubicin are currently in clinical use, but with safety issues involving each of them. The new ADC has the potential to increase the proapoptotic markers such as Bax, cleaved caspase 9, and Cytc at 5 and 10 μg/mL against the human breast tumor cell line BT474.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.